Toronto Dominion Bank Has $9.58 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Toronto Dominion Bank grew its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 75.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 230,320 shares of the company’s stock after purchasing an additional 98,843 shares during the quarter. Toronto Dominion Bank owned about 0.06% of Moderna worth $9,577,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MRNA. Wilmington Savings Fund Society FSB increased its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc acquired a new stake in Moderna during the 4th quarter worth about $37,000. Venturi Wealth Management LLC grew its holdings in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares during the period. Crowley Wealth Management Inc. bought a new position in shares of Moderna in the 4th quarter worth about $41,000. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock valued at $42,000 after purchasing an additional 343 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $27.99 on Wednesday. The firm has a market capitalization of $10.82 billion, a P/E ratio of -3.02 and a beta of 1.99. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The stock has a 50 day moving average price of $27.70 and a two-hundred day moving average price of $35.11.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analysts’ expectations of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna’s quarterly revenue was down 35.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($3.07) earnings per share. On average, equities analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of several research analyst reports. UBS Group cut their target price on Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Citigroup assumed coverage on shares of Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price objective for the company. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. Morgan Stanley cut their target price on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 9th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Friday, March 21st. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus target price of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.